Morepen Laboratories Limited (MOREPENLAB.NS)
INR 83.7
(-0.46%)
INR 83.7
(-0.46%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 289.99 Million INR | 15.24% |
| 2022 | 251.64 Million INR | 35.52% |
| 2021 | 185.69 Million INR | 8.94% |
| 2020 | 170.45 Million INR | 26.56% |
| 2019 | 134.68 Million INR | 12.76% |
| 2018 | 119.43 Million INR | -17.99% |
| 2017 | 145.64 Million INR | -70.99% |
| 2016 | 502.11 Million INR | 15.67% |
| 2015 | 434.11 Million INR | -32.7% |
| 2014 | 645 Million INR | -15.1% |
| 2013 | 759.7 Million INR | -19.74% |
| 2012 | 946.5 Million INR | -16.89% |
| 2011 | 1.13 Billion INR | -19.82% |
| 2010 | 1.42 Billion INR | 1.65% |
| 2009 | 1.39 Billion INR | -50.17% |
| 2008 | 2.8 Billion INR | -4.06% |
| 2007 | 2.92 Billion INR | -41.35% |
| 2006 | 4.98 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 289.99 Million INR | 15.24% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 277.55 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 289.99 Million INR | 0.0% |
| 2022 Q2 | 228.11 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 251.64 Million INR | 0.0% |
| 2022 FY | 251.64 Million INR | 35.52% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 185.69 Million INR | 8.94% |
| 2021 Q4 | 185.69 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 121.81 Million INR | 0.0% |
| 2020 Q2 | 159.26 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 170.45 Million INR | 0.0% |
| 2020 FY | 170.45 Million INR | 26.56% |
| 2020 Q1 | - INR | -100.0% |
| 2019 FY | 134.68 Million INR | 12.76% |
| 2019 Q4 | 134.68 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 158.27 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 FY | 119.43 Million INR | -17.99% |
| 2018 Q2 | 24.71 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 119.43 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | 0.0% |
| 2017 FY | 145.64 Million INR | -70.99% |
| 2017 Q4 | 145.64 Million INR | 0.0% |
| 2016 FY | 502.11 Million INR | 15.67% |
| 2015 FY | 434.11 Million INR | -32.7% |
| 2014 FY | 645 Million INR | -15.1% |
| 2013 FY | 759.7 Million INR | -19.74% |
| 2012 FY | 946.5 Million INR | -16.89% |
| 2011 FY | 1.13 Billion INR | -19.82% |
| 2010 FY | 1.42 Billion INR | 1.65% |
| 2009 FY | 1.39 Billion INR | -50.17% |
| 2008 FY | 2.8 Billion INR | -4.06% |
| 2007 FY | 2.92 Billion INR | -41.35% |
| 2006 FY | 4.98 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 1.43 Billion INR | 79.728% |
| Ind-Swift Limited | 10.13 Billion INR | 97.14% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 91.287% |
| Sakar Healthcare Limited | 793.51 Million INR | 63.455% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 99.564% |
| Innova Captab Limited | 2.45 Billion INR | 88.169% |
| Divi's Laboratories Limited | 30 Million INR | -866.64% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -530.664% |
| Mankind Pharma Limited | 2.07 Billion INR | 86.002% |
| Sequent Scientific Limited | 4.87 Billion INR | 94.054% |
| Wanbury Limited | 1.16 Billion INR | 75.105% |
| Laurus Labs Limited | 25.77 Billion INR | 98.875% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 95.437% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -69.111% |
| Alembic Limited | 91.5 Million INR | -216.931% |
| Hikal Limited | 8.17 Billion INR | 96.453% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 94.349% |
| Neuland Laboratories Limited | 953.89 Million INR | 69.599% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 92.321% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 97.644% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | 11.48% |
| Themis Medicare Limited | 957.92 Million INR | 69.727% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 96.394% |
| Lupin Limited | 29.21 Billion INR | 99.007% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -1577.903% |
| Wockhardt Limited | 23.56 Billion INR | 98.769% |
| Vaishali Pharma Limited | 134.91 Million INR | -114.939% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 89.834% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -224.34% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 99.209% |
| FDC Limited | 205.18 Million INR | -41.332% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 98.551% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | 8.365% |
| Eris Lifesciences Limited | 27.81 Billion INR | 98.957% |
| Venus Remedies Limited | 413.3 Million INR | 29.835% |
| ZIM Laboratories Limited | 1.08 Billion INR | 73.352% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 70.954% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -1372.041% |
| Shilpa Medicare Limited | 9.37 Billion INR | 96.906% |
| Albert David Limited | 33.24 Million INR | -772.366% |
| Ajanta Pharma Limited | 352.8 Million INR | 17.803% |
| Hester Biosciences Limited | 2.44 Billion INR | 88.133% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | 55.383% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 97.133% |
| Gufic Biosciences Limited | 3.32 Billion INR | 91.289% |
| Windlas Biotech Limited | 36.41 Million INR | -696.463% |
| Procter & Gamble Health Limited | 95.6 Million INR | -203.339% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | 7.505% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 70.557% |
| Granules India Limited | 13.15 Billion INR | 97.795% |
| Aarti Drugs Limited | 5.64 Billion INR | 94.861% |
| Bal Pharma Limited | 1.39 Billion INR | 79.234% |
| Alkem Laboratories Limited | 14.18 Billion INR | 97.956% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 99.114% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -2618.335% |
| Medicamen Biotech Limited | 308.17 Million INR | 5.899% |
| Unichem Laboratories Limited | 2.47 Billion INR | 88.284% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | -18.901% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -6507.245% |
| Valiant Laboratories Limited | 767.08 Million INR | 62.196% |
| Orchid Pharma Limited | 1.35 Billion INR | 78.548% |
| Medico Remedies Limited | 80.5 Million INR | -260.221% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -74.467% |
| Ipca Laboratories Limited | 14.38 Billion INR | 97.984% |
| Brooks Laboratories Limited | 56.41 Million INR | -413.997% |
| Syncom Formulations (India) Limited | 724.86 Million INR | 59.994% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.946% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 99.279% |
| NATCO Pharma Limited | 3.71 Billion INR | 92.188% |
| Suven Life Sciences Limited | 7.09 Million INR | -3986.121% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 85.008% |
| Strides Pharma Science Limited | 25.16 Billion INR | 98.848% |
| Indoco Remedies Limited | 6.71 Billion INR | 95.684% |
| Alpa Laboratories Limited | 52.46 Million INR | -452.734% |
| Lasa Supergenerics Limited | 220.76 Million INR | -31.36% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | 52.577% |